Anuncio • May 12
Vary Tech, Evonik and Supezet Launch Full-Chain Chemical Recycling Package for Waste Plastics to High-Quality Ppo and Circular Naphtha Vary Tech, a global leader in solid waste resource utilization, together with Evonik and SupeZET, officially launched a full-industry chain process package for chemically recycling waste plastics into high-quality Plastic Pyrolysis Oil (PPO) and circular naphtha. The core technology is Vary Tech's oxygen-free pyrolysis, developed over 20 years and six iterations. With a single-unit capacity of 150 tons/day and over 8,000 operating hours annually, it ensures high front-end stability. The PPO then enters Evonik's proprietary Rocket module for upgrading and impurity removal, followed by SupeZET's advanced hydrogenation and fractionation for deep refining. The complete chain — feedstock pretreatment, continuous pyrolysis, deep purification, and product offtake — directly outputs circular naphtha and high-quality PPO meeting international petrochemical standards. This ensures seamless entry into global petrochemical and low-carbon fuel supply chains, removing technical barriers to the high-end circular economy. As the core engine, Vary Tech's oxygen-free pyrolysis technology offers broad feedstock compatibility. Beyond waste plastics, it has been applied to waste tires, oil sludge, industrial hazardous waste, medical waste, and new energy solid waste, with over 100 commercial pyrolysis lines delivered globally. While building chemical recycling, Vary Tech also leads in mechanical recycling. Leveraging 16 years of self-operated plant experience and its "high-end equipment manufacturing + industrial operation" dual-drive model, Vary Tech showcased its AI-powered intelligent home appliance dismantling system at the exhibition. Achieving 200 units per hour — a global efficiency record — the system delivers high-purity separation of all e-waste categories. Vary Tech has empowered Haier, TCL, and Midea, providing green recycling services for over 130 million obsolete appliances worldwide. From mechanical to chemical recycling, Vary Tech is integrating global supply chain resources to deliver scalable, economical, and sustainable technical solutions for global climate action and circular economy goals. Reported Earnings • May 11
First quarter 2026 earnings released: EPS: €0.27 (vs €0.50 in 1Q 2025) First quarter 2026 results: EPS: €0.27 (down from €0.50 in 1Q 2025). Revenue: €3.43b (down 9.3% from 1Q 2025). Net income: €125.0m (down 46% from 1Q 2025). Profit margin: 3.6% (down from 6.2% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Anuncio • Apr 17
Evonik Industries AG, Annual General Meeting, Jun 03, 2026 Evonik Industries AG, Annual General Meeting, Jun 03, 2026, at 10:00 W. Europe Standard Time. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €16.44, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Chemicals industry in Europe. Total returns to shareholders of 2.3% over the past three years. New Risk • Mar 08
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (176% payout ratio). Large one-off items impacting financial results. Declared Dividend • Mar 02
Dividend reduced to €1.00 Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 7.0%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk. Declared Dividend • Feb 08
Dividend reduced to €1.00 Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 6.7%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk. Reported Earnings • Feb 06
Full year 2025 earnings released: EPS: €1.36 (vs €0.48 in FY 2024) Full year 2025 results: EPS: €1.36 (up from €0.48 in FY 2024). Revenue: €14.1b (down 7.2% from FY 2024). Net income: €634.0m (up 186% from FY 2024). Profit margin: 4.5% (up from 1.5% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Anuncio • Feb 06
Evonik Industries AG announces Annual dividend, payable on June 08, 2026 Evonik Industries AG announced Annual dividend of EUR 1.0000 per share payable on June 08, 2026, ex-date on June 04, 2026 and record date on June 05, 2026. Reported Earnings • Nov 05
Third quarter 2025 earnings released: €0.23 loss per share (vs €0.48 profit in 3Q 2024) Third quarter 2025 results: €0.23 loss per share (down from €0.48 profit in 3Q 2024). Revenue: €3.39b (down 12% from 3Q 2024). Net loss: €106.0m (down 148% from profit in 3Q 2024). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year. Anuncio • Oct 06
Evonik Industries AG to Report Q4, 2025 Results on Mar 04, 2026 Evonik Industries AG announced that they will report Q4, 2025 results on Mar 04, 2026 Anuncio • Sep 26
Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025 Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024. Reported Earnings • Aug 03
Second quarter 2025 earnings released: EPS: €0.26 (vs €0.011 loss in 2Q 2024) Second quarter 2025 results: EPS: €0.26 (up from €0.011 loss in 2Q 2024). Revenue: €3.50b (down 11% from 2Q 2024). Net income: €120.0m (up €125.0m from 2Q 2024). Profit margin: 3.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 22
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 03 June 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.8%. Within top quartile of Austrian dividend payers (4.8%). Higher than average of industry peers (2.5%). Reported Earnings • May 13
First quarter 2025 earnings released: EPS: €0.50 (vs €0.33 in 1Q 2024) First quarter 2025 results: EPS: €0.50 (up from €0.33 in 1Q 2024). Revenue: €3.78b (flat on 1Q 2024). Net income: €233.0m (up 49% from 1Q 2024). Profit margin: 6.2% (up from 4.1% in 1Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Declared Dividend • Mar 31
Dividend of €1.17 announced Dividend of €1.17 is the same as last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 5.9%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio). However, it is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 1.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 114% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Anuncio • Mar 06
Evonik Industries AG announces Annual dividend, payable on June 02, 2025 Evonik Industries AG announced Annual dividend of EUR 1.1700 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025. Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: €0.48 (vs €0.21 loss in 3Q 2023) Third quarter 2024 results: EPS: €0.48 (up from €0.21 loss in 3Q 2023). Revenue: €3.83b (up 1.6% from 3Q 2023). Net income: €223.0m (up €319.0m from 3Q 2023). Profit margin: 5.8% (up from net loss in 3Q 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Anuncio • Sep 20
Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025 Evonik Industries AG announced that they will report Q1, 2025 results on May 12, 2025 Reported Earnings • Aug 02
Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023) Second quarter 2024 results: €0.01 loss per share (improved from €0.58 loss in 2Q 2023). Revenue: €3.93b (up 1.1% from 2Q 2023). Net loss: €5.00m (loss narrowed 98% from 2Q 2023). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 29
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 05 June 2024. Payment date: 07 June 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 5.8%. Lower than top quartile of Austrian dividend payers (6.1%). Higher than average of industry peers (2.7%). Reported Earnings • May 09
First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023) First quarter 2024 results: EPS: €0.33 (up from €0.10 in 1Q 2023). Revenue: €3.80b (down 5.2% from 1Q 2023). Net income: €156.0m (up 232% from 1Q 2023). Profit margin: 4.1% (up from 1.2% in 1Q 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 05
Full year 2023 earnings released: €1.00 loss per share (vs €1.16 profit in FY 2022) Full year 2023 results: €1.00 loss per share (down from €1.16 profit in FY 2022). Revenue: €15.3b (down 17% from FY 2022). Net loss: €465.0m (down 186% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Anuncio • Mar 05
International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik. International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik on March 4, 2024. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities. Anuncio • Jan 16
Lanxess Reportedly Seeks to Sell Polyurethane Ops LANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals. Reported Earnings • Nov 08
Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022) Third quarter 2023 results: €0.21 loss per share (down from €0.46 profit in 3Q 2022). Revenue: €3.77b (down 23% from 3Q 2022). Net loss: €96.0m (down 145% from profit in 3Q 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 11
Second quarter 2023 earnings released: €0.58 loss per share (vs €0.64 profit in 2Q 2022) Second quarter 2023 results: €0.58 loss per share (down from €0.64 profit in 2Q 2022). Revenue: €3.89b (down 19% from 2Q 2022). Net loss: €270.0m (down 191% from profit in 2Q 2022). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Anuncio • Jul 12
Evonik Industries AG Revises Financial Guidance for the Full Year 2023 Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion). Anuncio • Jun 09
RAG Stiftung Not in Hurry to Cut Evonik Stake RAG-Stiftung is not in a hurry to reduce its stake in chemicals firm Evonik Industries AG (XTRA:EVK) as the foundation is not under financial pressure, RAG chairman Bernd Toenjes said at a press conference as quotes by German paper Frankfurter Allgemeine Zeitung (FAZ). RAG Stiftung, which owns 54.9% in the chemicals company, plans to cut its stake to a blocking minority in the future. The shareholding may fall below the majority threshold soon. According to Toenjes, a convertible bond is due in 2024, providing an opportunity to reach 50% by the end of 2024. For the moment, Evonik remains one of the most important assets for RAG Stiftung. Upcoming Dividend • May 25
Upcoming dividend of €1.17 per share at 5.9% yield Eligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 5.9%. Within top quartile of Austrian dividend payers (5.4%). Higher than average of industry peers (4.0%). Reported Earnings • May 10
First quarter 2023 earnings released: EPS: €0.10 (vs €0.67 in 1Q 2022) First quarter 2023 results: EPS: €0.10 (down from €0.67 in 1Q 2022). Revenue: €4.01b (down 11% from 1Q 2022). Net income: €47.0m (down 85% from 1Q 2022). Profit margin: 1.2% (down from 7.0% in 1Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 03
Full year 2022 earnings released: EPS: €1.16 (vs €1.61 in FY 2021) Full year 2022 results: EPS: €1.16 (down from €1.61 in FY 2021). Revenue: €18.5b (up 24% from FY 2021). Net income: €539.0m (down 28% from FY 2021). Profit margin: 2.9% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Anuncio • Dec 30
SABO S.p.A. acquired TAA derivatives business from Evonik Industries AG (XTRA:EVK). SABO S.p.A. agreed to acquire TAA derivatives business from Evonik Industries AG (XTRA:EVK) on October 21, 2022. On the sales price, no details are disclosed. The transaction is subject to approval by the competent Evonik committees. Around 250 employees to transfer to new owner. Around 250 people are working at the two production sites in Marl, Germany, and Liaoyang, China. The closing is expected to be in early 2023.
SABO S.p.A. completed the acquisition of TAA derivatives business from Evonik Industries AG (XTRA:EVK) on December 29, 2022. Reported Earnings • Nov 10
Third quarter 2022 earnings released: EPS: €0.46 (vs €0.49 in 3Q 2021) Third quarter 2022 results: EPS: €0.46 (down from €0.49 in 3Q 2021). Revenue: €4.88b (up 26% from 3Q 2021). Net income: €214.0m (down 7.4% from 3Q 2021). Profit margin: 4.4% (down from 6.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Anuncio • Nov 02
Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK). Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022.
Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on November 1, 2022 Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2021) Second quarter 2022 results: EPS: €0.64 (up from €0.48 in 2Q 2021). Revenue: €4.77b (up 31% from 2Q 2021). Net income: €297.0m (up 34% from 2Q 2021). Profit margin: 6.2% (up from 6.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 14% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Anuncio • Aug 03
Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022. Anuncio • Jun 25
Evonik Industries AG, Annual General Meeting, May 31, 2023 Evonik Industries AG, Annual General Meeting, May 31, 2023. Agenda: Annual shareholders' meeting 2023. Upcoming Dividend • May 19
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 26 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 63% and this is well supported by cash flows. Trailing yield: 4.5%. Within top quartile of Austrian dividend payers (4.5%). Higher than average of industry peers (3.4%). Reported Earnings • May 06
First quarter 2022 earnings released: EPS: €0.67 (vs €0.41 in 1Q 2021) First quarter 2022 results: EPS: €0.67 (up from €0.41 in 1Q 2021). Revenue: €4.50b (up 34% from 1Q 2021). Net income: €314.0m (up 63% from 1Q 2021). Profit margin: 7.0% (up from 5.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.8%, compared to a 17% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Anuncio • Apr 22
Evonik Industries AG Provides Earnings Guidance for the Full Year 2022 Evonik Industries AG provided earnings guidance for the full year 2022. For the year, the company expects sales of between €15.5 billion and €16.5 billion. Reported Earnings • Mar 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: €1.61 (up from €1.05 in FY 2020). Revenue: €15.0b (up 23% from FY 2020). Net income: €748.0m (up 53% from FY 2020). Profit margin: 5.0% (up from 4.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Over the next year, revenue is forecast to grow 2.9%, compared to a 12% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has remained flat. Anuncio • Mar 04
Evonik Industries AG to Report Q4, 2022 Results on Mar 02, 2023 Evonik Industries AG announced that they will report Q4, 2022 results on Mar 02, 2023 Reported Earnings • Nov 06
Third quarter 2021 earnings released: EPS €0.49 (vs €0.32 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €3.87b (up 33% from 3Q 2020). Net income: €231.0m (up 55% from 3Q 2020). Profit margin: 6.0% (up from 5.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Reported Earnings • Aug 06
Second quarter 2021 earnings released: EPS €0.48 (vs €0.26 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €3.64b (up 29% from 2Q 2020). Net income: €221.0m (up 77% from 2Q 2020). Profit margin: 6.1% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Anuncio • Aug 04
Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH. Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH on August 2, 2021. Upon completion the employees of JeNaCell will continue to work at the development and production site based in Jena, Germany and JeNaCell's portfolio will be integrated into Evonik's health care business.
Evonik Industries AG (XTRA:EVK) completed the acquisition of JeNaCell GmbH on August 2, 2021. Anuncio • Jun 23
Orion Engineered Carbons S.A. Settles Dispute with Evonik Industries AG Orion Engineered Carbons S.A. announced its agreement with Evonik Industries AG to settle the arbitration proceedings which Orion (Germany) had commenced against an Evonik Industries AG affiliate in June 2019. The arbitration was launched by Orion to enforce - among others - indemnity claims covering capital expenditures and costs to remedy past violations of the U.S. Clean Air Act alleged by the U.S. Environmental Protection Agency (U.S. EPA). According to the settlement, Evonik agrees to make a one-time cash payment of €66.55 million (approximately $79.3 million) to Orion which resolves the claims and counterclaims the parties raised in the arbitration. The settled dispute between Orion and Evonik originates from the acquisition of the carbon black business by Rhône Capital and Triton after the business was spun-out of Evonik in 2011. The 2011 acquisition agreement provided for a partial indemnity from Evonik against various exposures, including capital investments, fines and costs arising in connection with U.S. Clean Air Act violations that allegedly occurred prior to the closing of the 2011 acquisition (i.e., under Evonik’s control). The respective claims raised by the U.S. EPA were ultimately resolved by a Consent Decree between Orion and the U.S. EPA in June 2018. Under the Consent Decree, Orion became obligated to install certain capital-intensive pollution control equipment at its U.S. carbon black plants. In June 2019, Orion initiated arbitration proceedings to enforce its environmental indemnity claims against Evonik, and Evonik in turn submitted certain counterclaims related to tax indemnities and cost reimbursements against Orion. The settlement now reached by Orion and Evonik terminates the arbitration and puts an end to a legal controversy that lasted for almost a decade. Upcoming Dividend • May 27
Upcoming dividend of €1.15 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 08 June 2021. Trailing yield: 4.0%. Within top quartile of Austrian dividend payers (3.2%). Higher than average of industry peers (2.3%). Reported Earnings • May 07
First quarter 2021 earnings released: EPS €0.41 (vs €0.29 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €3.36b (up 3.5% from 1Q 2020). Net income: €193.0m (up 42% from 1Q 2020). Profit margin: 5.7% (up from 4.2% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 06
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €12.2b (down 6.9% from FY 2019). Net income: €489.0m (down 35% from FY 2019). Profit margin: 4.0% (down from 5.7% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 06
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 5.8%, compared to a 5.8% growth forecast for the Chemicals industry in Austria. Is New 90 Day High Low • Feb 20
New 90-day high: €28.03 The company is up 18% from its price of €23.83 on 20 November 2020. The Austrian market is also up 18% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.22 per share. Anuncio • Feb 13
Evonik Industries AG to Report Q4, 2020 Results on Mar 04, 2021 Evonik Industries AG announced that they will report Q4, 2020 results on Mar 04, 2021 Is New 90 Day High Low • Jan 29
New 90-day high: €27.45 The company is up 32% from its price of €20.82 on 30 October 2020. The Austrian market is up 39% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €52.93 per share. Is New 90 Day High Low • Jan 06
New 90-day high: €27.33 The company is up 16% from its price of €23.50 on 08 October 2020. The Austrian market is up 27% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.41 per share. Anuncio • Jan 06
Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million. Evonik Industries AG (XTRA:EVK) signed an agreement to acquire LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million on December 4, 2020. Under the terms of the agreement, Evonik agreed to pay DURECT the sum of $15 million in exchange for certain assets and liabilities associated with LACTEL product line based in Birmingham, Alabama, plus an additional potential payment based on full year EBITDAS results. The consideration is subject to adjustments based on the year-end net working capital. An offer will be extended to each of the 15 employees of DURECT located in Birmingham, Alabama, which are associated with the LACTEL® business to transition to Evonik. The transaction is subject to certain customary closing conditions and is expected to occur by the first quarter of 2021.
Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) on January 4, 2021. Is New 90 Day High Low • Dec 16
New 90-day high: €26.75 The company is up 15% from its price of €23.28 on 17 September 2020. The Austrian market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €44.44 per share. Anuncio • Dec 12
Evonik Industries AG to Report Q2, 2021 Results on Aug 05, 2021 Evonik Industries AG announced that they will report Q2, 2021 results on Aug 05, 2021 Is New 90 Day High Low • Nov 24
New 90-day high: €25.11 The company is up 2.0% from its price of €24.67 on 26 August 2020. The Austrian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €39.61 per share. Reported Earnings • Nov 05
Third quarter 2020 earnings released: EPS €0.32 The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2020 results: Revenue: €2.92b (down 9.7% from 3Q 2019). Net income: €149.0m (down 2.6% from 3Q 2019). Profit margin: 5.1% (up from 4.7% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Nov 05
Revenue beats expectations Revenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 3.9% while the growth in Chemicals industry in Austria is expected to stay flat. Is New 90 Day High Low • Oct 21
New 90-day low: €21.93 The company is down 12% from its price of €24.87 on 23 July 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.16 per share. Is New 90 Day High Low • Sep 26
New 90-day low: €21.99 The company is down 4.0% from its price of €22.84 on 26 June 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €40.52 per share. Anuncio • Aug 27
Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million. Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million on August 26, 2020. The purchase price (enterprise value) is 9.1x times adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in 2019. The transaction will be financed out of Evonik's strong cash position. Porocel generated sales of approximately $100 million and EBITDA of about $23 million in 2019. The transaction is expected to close by the end of 2020 and is subject to approval by the relevant authorities. Evonik expects to increase sales of the combined catalyst business to significantly more than $591 million (€500 million) by the end of 2025 without the need for investment in new capacities. RBC Capital Markets acted as financial advisor and Thompson Hine LLP acted as legal advisor to Porocel. Dieter Schmitz (US), Matthew Grant (Canada), Tracy Wut (China), Jean-Francois Findling (Luxembourg), Andrew Martin (Singapore), John Murphy, Garry Jaunal, Kai Kramer, Doug Sanders, Jessica Wicha, Brian Zurawski and Richard Wells of Baker McKenzie acted as legal advisor to Evonik Industries. Anuncio • Jul 31
Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.l Evonik Industries AG (XTRA:EVK) entered into an agreement to acquire to acquire Innovativehealth Group,s.l on March 19, 2020. Innovativehealth will be part of Evonik's Care Solutions Business Line. The transaction is expected to close before the end of March 2020.
Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.l on April 1, 2020. Innovativehealth GROUP,S.L. will be part of Evonik's Care Solutions Business Line. Anuncio • Jul 30
United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK). United Initiators GmbH agreed to acquire Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020. The sale has been initiated to address the Competition Bureau about its proposed transaction for the takeover of PeroxyChem Holding Company LLC. The deal has been approved by the Competition Bureau.
United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020.